Medicare Payment Increase in Final Budget Reconciliation Bill
The bill includes a 2.5% increase to the Medicare Physician Fee Schedule for calendar year 2026.
Read moreMain Content
New Mammography Quality Measures Available for Beta Testing
Feb. 8, 2024
The Centers for Medicare and Medicaid Services (CMS) Measures Management System posted a public comment period, open through Feb. 26, for four new breast cancer-related measures developed by Acumen, LLC. These include three quality measures and one episode-based cost measure intended to assess clinician performance in breast cancer screening and diagnosis and improve patient outcomes. An informational webinar about the measures will be held Feb. 13, 3–4pm ET.
The codes are:
- Breast Cancer Screening Recall Rate Quality Measure (Outcome).
- Breast Cancer Screening with an Eventual Breast Cancer Diagnosis: Positive Predictive Value 1 (PPV1) Quality Measure (Outcome).
- Use of Biopsy After Diagnostic Follow-up with an Eventual Breast Cancer Diagnosis: Positive Predictive Value 3 (PPV3) Quality Measure (Outcome).
- Breast Cancer Screening Episode-Based Cost Measure.
The testing process is an important step in determining whether these measures could eventually be adopted into CMS’ Merit-based Incentive Payment System. Feedback can be provided via the 2024 Beta Testing Feedback Survey through 11:59pm ET, Feb. 26.
If you have questions, contact Samantha Shugarman, American College of Radiology® Director of Quality Programs.
Related ACR News
CMS Announces Prior Authorization Test Model
WiSer is a six-year program that will begin in six states on January 1, 2026. It will introduce prior authorization using AI technology for a select number of services, including some IR procedures.
Read moreSupreme Court Upholds Preventive Services Coverage
ACR commends the Supreme Court’s ruling affirming the constitutionality of the structure and appointment process of the U.S. Preventive Services Task Force.
Read more